Mingwei Fu
- Nephrology top 10%
-
- Lymphoma Diagnosis and Treatment 7
-
- Acute Lymphoblastic Leukemia research 6
-
- Chronic Lymphocytic Leukemia Research 5
-
- Chronic Myeloid Leukemia Treatments 4
- Multiple Myeloma Research and Treatments 3
-
- CNS Lymphoma Diagnosis and Treatment 3
-
- CAR-T cell therapy research 3
-
- Crystallography and molecular interactions 3
- Partner nations
- ChinaUnited StatesNamibia
In The Last Decade
Mingwei Fu
29 papers receiving 536 citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Cancer Research 159
- Nephrology 75
- Pulmonary and Respiratory Medicine 185
- Geriatrics and Gerontology 22
- Molecular Biology 249
Countries citing papers authored by Mingwei Fu
This map shows the geographic impact of Mingwei Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingwei Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingwei Fu more than expected).
Fields of papers citing papers by Mingwei Fu
This network shows the impact of papers produced by Mingwei Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingwei Fu. The network helps show where Mingwei Fu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mingwei Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 3 | |
| 8 | 2024 | 1 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 2 | |
| 12 | 2022 | 17 | |
| 13 | Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcificationbreakdown → | 2022 | 238 |
| 14 | 2021 | 44 | |
| 15 | 2021 | 2 | |
| 16 | 2020 | 25 | |
| 17 | 2020 | 1 | |
| 18 | 2015 | 3 | |
| 19 | [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia]. | 2011 | 1 |
| 20 | 2009 | 11 |
About Mingwei Fu
Mingwei Fu is a scholar working on General Engineering, Hematology, Genetics, Geriatrics and Gerontology and Pathology and Forensic Medicine, having authored 35 papers that have together received 536 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Acute Lymphoblastic Leukemia research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers), CNS Lymphoma Diagnosis and Treatment (3 papers), Multiple Myeloma Research and Treatments (3 papers), CAR-T cell therapy research (3 papers) and Crystallography and molecular interactions (3 papers). The work is most often cited by research in Cancer Research (159 citations), Nephrology (75 citations), Pulmonary and Respiratory Medicine (185 citations), Geriatrics and Gerontology (22 citations) and Molecular Biology (249 citations). Mingwei Fu has collaborated with scholars based in China, United States and Namibia. Frequent co-authors include Qianqian Dong, An Chen, Lihe Lu, Yining Li, Jianyun Yan, Xiaoyu Liu, Zirong Lan, Yuanzhi Ye, Qingchun Liang and Jing‐Song Ou. Their work appears in journals such as Blood, Kidney International, Crystal Growth & Design, Acta Pharmaceutica Sinica B and Journal of Molecular and Cellular Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.